Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness

This study has been completed.
Sponsor:
Collaborator:
Royal University Hospital Foundation
Information provided by:
University of Saskatchewan
ClinicalTrials.gov Identifier:
NCT00605410
First received: January 18, 2008
Last updated: January 6, 2009
Last verified: July 2008

January 18, 2008
January 6, 2009
January 2008
April 2008   (final data collection date for primary outcome measure)
methacholine PC20 [ Time Frame: 6hours and 12 hours post inhalation ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00605410 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness
Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness

Certain lung disease medications can influence diagnostic tests and research investigations. This study will investigate how long ipratropium bromide must be withheld before a methacholine challenge test can be conducted. This information will be useful for validating current guidelines.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Asthma
  • Drug: ipratropium bromide
    2 puffs (40 micrograms) 2 puffs (0micrograms)
    Other Name: Atrovent HFA Inhalation Aerosol
  • Drug: placebo
    Matched placebo
  • Active Comparator: 1
    Intervention: Drug: ipratropium bromide
  • Placebo Comparator: 2
    Intervention: Drug: placebo
Illamperuma C, Davis BE, Fenton ME, Cockcroft DW. Duration of bronchoprotection of inhaled ipratropium against inhaled methacholine. Ann Allergy Asthma Immunol. 2009 May;102(5):438-9. No abstract available.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
April 2008
April 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of asthma; stable and controlled
  • FEV1 greater than or equal to 65% predicted

Exclusion Criteria:

  • Concomitant lung disease other than asthma
Both
19 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00605410
BIO 07-161
No
Dr. Donald W. Cockcroft, Department of Medicine, University of Saskatchewan
University of Saskatchewan
Royal University Hospital Foundation
Principal Investigator: Donald W Cockcroft, MD Department of Medicine University of Saskatchewan
University of Saskatchewan
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP